Vistalab Technologies Inc Brewster, NY - 10509

Vistalab Technologies Inc is categorized under Pipettes, Hemocytometer in Brewster, NY and active since 1994.

Vistalab Technologies Inc was established in 1994, and today employs 1 to 4, earning $2.500.000 to $4.999.999 per year. This is a Pipettes, Hemocytometer business, which does work in the B2B market, and is classified as a Pipettes, Hemocytometer, under code number 333249 by the NAICS.

If you are seeking more information, feel free to contact Richard Scordato at the company’s single location by writing to 2 Geneva Road, Brewster, New York NY 10509 or by phoning (914) 244-6226. You can also visit this business on Facebook by going to their profile page at Facebook or on find them on Twitter.

Business Name: Vistalab Technologies Inc
Contact Person: Richard Scordato
Address: 2 Geneva Road, Brewster, New York 10509
Phone Number: (914) 244-6226
Website Address: ovationpipette.com
Annual Revenue (USD): $2.500.000 to $4.999.999
Founded: 1994
Location Type: Single Location
Employee Number: 1 to 4
Business Type: B2B (Business to Business)
Business Category: Pipettes, Hemocytometer
SIC Code: 3821
NAICS Code: 333249
Share This Business:

Vistalab Technologies Inc was started in 1994 to provide professional Pipettes, Hemocytometer under the SIC code 3821 and NAICS code 333249. Since its inception, the company has gone on to take a total of 1 to 4 personnel under its employment and has achieved earnings of $2.500.000 to $4.999.999 per annum.

Feel free to contact Richard Scordato for inquiries that concern Vistalab Technologies Inc by calling the company number (914) 244-6226, as your correspondence is most welcome. Additionally, the physical location of the single location of Vistalab Technologies Inc can be found at the coordinates 41.42896,-73.626439 as well as the street address 2 Geneva Road in Brewster, New York 10509.

For its online presence, you may visit Vistalab Technologies Inc’s website at ovationpipette.com and engage with its social media outlets through on Twitter and on Facebook.